骨髓增生异常综合征的中医辨证论治(4)
脾肾阳虚型患者对复方青黄散的治疗反应好于肝肾阴虚型，与中医辨证用药规律相符。辨证分型有利于为患者提供精準治疗方案。
参考文献
[1]胡晓梅，唐旭东，麻柔，等.骨髓生异常综合征发病机制的研究进展[J].国际输血及血液学杂志，2006，29(2)：132-136.
[2]Vanlet P，Horny HP，Bennet JM，et al.Definitions and standards in the diagnosis and treatment of myelodysplatic snydromes：Consensus statements and report from a working conference[J].Leuk Res，2007，31(6)：727-736.
[3]Swerdlow SH，Campo E，Harris NL，et al.WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues[S].Lyon，France：IARC，2008，p88-93.
[4]Shaffer LG，Tommerup N.An international system for human cytogenetic nomenclature(ISCN，2005)[M].Basel：S.Karger Publishers，2005.
[5]Tefferi A，Barosi G，Mesa RA，et al.International Working Group(IWG)consensus criteria for treatment response in myelofibrosis with myeloid metaplasia：On behalf of the IWG for myelofibrosis research and treatment(IWG-MRT)[J].Blood，2006，108(5)：1497-1503.
[6]王月，方苏，宋敏敏，等.“阳虚寒毒”理论在诊治骨髓增生异常综合征中的应用[J].北京中医药，2013，32(11)：9-11.
[7]王月，宋敏敏，方苏，等.复方青黄散治疗骨髓增生异常综合征的临床安全性分析[J].国际中医中药杂志，2014，36(12)：1074-1077.
[8]王月，方苏，邓中阳，等.复方青黄散治疗骨髓增生异常综合征的临床疗效[J].国际中医中药杂志，2015，37(12)：1091-1094.
[9]Hu XM，Tanaka S，Onda K，et al.Arsenic disulfide induced apoptosis and concurrently promoted erythroid differentiation in cytokine-dependent MDS-progressed leukemia cell line F-36p with complex karyotype including monosomy 7[J].Chin J Integr Med，2014，20(5)：387-393.
[10]Hu XM，Yuan B，Tanaka S，et al.Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines[J].Hematology，2014，19(6)：352-360.
[11]Hu XM，Yuan B，Tanaka S，et al.Involvement of oxidative stress associated with glutathione depletion and p38 MAPK activation in arsenic disulfide-induced differentiation in HL-60 cells[J].Leuk Lymphom，2014，55(2)：392-404.
[12]Hu XM，Yuan B，Song MM，et al.Dose-dependent biphasic effects of arsenic disulfide on differentiation and apoptosis of HL-60 cells[J].Current Topics in Pharmacology，2014，17(2)：13-25., http://www.100md.com(赵攀 邓中阳 王明镜 宋敏敏 胡晓梅)
参考文献
[1]胡晓梅，唐旭东，麻柔，等.骨髓生异常综合征发病机制的研究进展[J].国际输血及血液学杂志，2006，29(2)：132-136.
[2]Vanlet P，Horny HP，Bennet JM，et al.Definitions and standards in the diagnosis and treatment of myelodysplatic snydromes：Consensus statements and report from a working conference[J].Leuk Res，2007，31(6)：727-736.
[3]Swerdlow SH，Campo E，Harris NL，et al.WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues[S].Lyon，France：IARC，2008，p88-93.
[4]Shaffer LG，Tommerup N.An international system for human cytogenetic nomenclature(ISCN，2005)[M].Basel：S.Karger Publishers，2005.
[5]Tefferi A，Barosi G，Mesa RA，et al.International Working Group(IWG)consensus criteria for treatment response in myelofibrosis with myeloid metaplasia：On behalf of the IWG for myelofibrosis research and treatment(IWG-MRT)[J].Blood，2006，108(5)：1497-1503.
[6]王月，方苏，宋敏敏，等.“阳虚寒毒”理论在诊治骨髓增生异常综合征中的应用[J].北京中医药，2013，32(11)：9-11.
[7]王月，宋敏敏，方苏，等.复方青黄散治疗骨髓增生异常综合征的临床安全性分析[J].国际中医中药杂志，2014，36(12)：1074-1077.
[8]王月，方苏，邓中阳，等.复方青黄散治疗骨髓增生异常综合征的临床疗效[J].国际中医中药杂志，2015，37(12)：1091-1094.
[9]Hu XM，Tanaka S，Onda K，et al.Arsenic disulfide induced apoptosis and concurrently promoted erythroid differentiation in cytokine-dependent MDS-progressed leukemia cell line F-36p with complex karyotype including monosomy 7[J].Chin J Integr Med，2014，20(5)：387-393.
[10]Hu XM，Yuan B，Tanaka S，et al.Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines[J].Hematology，2014，19(6)：352-360.
[11]Hu XM，Yuan B，Tanaka S，et al.Involvement of oxidative stress associated with glutathione depletion and p38 MAPK activation in arsenic disulfide-induced differentiation in HL-60 cells[J].Leuk Lymphom，2014，55(2)：392-404.
[12]Hu XM，Yuan B，Song MM，et al.Dose-dependent biphasic effects of arsenic disulfide on differentiation and apoptosis of HL-60 cells[J].Current Topics in Pharmacology，2014，17(2)：13-25., http://www.100md.com(赵攀 邓中阳 王明镜 宋敏敏 胡晓梅)